Skip to main content
SpringerLink
Log in

Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma

An Illinois Cancer Council study

  • Brief Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Clinical Brochure: Caracemide (NSC 253272). National Cancer Institute, National Institutes of Health, Bethesda, Maryland, August 1986

  2. Moore EC, Loo TL: Inhibition of ribonucleotide reductase by caracemide. Cancer Treat Rep 68(10):1293–1296, 1984

    Google Scholar 

  3. Savarajk N, Lu K, Fuen LG, Newman RA, Robbins VW, Gray KN, Loo TL: Pharmacokinetics of caracemide (Car, NSC-253272) in dogs. Proc Am Assoc Cancer Res 26:359, 1985

    Google Scholar 

  4. Raber MN, Adams F, Kavanaugh J, Legha S, Dimery I, Krakoff I: Phase I trial of caracemide using bolus and infusion schedules. Cancer Treat Rep 71(4):349–352, 1987

    Google Scholar 

  5. Bolani CP, Eisenberger M, Van Echo D, Hiponia D, Aisner J: Phase II study of caracemide in advanced or recurrent non-small cell lung cancer. Cancer Treat Rep 71(11): 1099–1100, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Section, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA

    Thomas Lad, Joel Schor, Michael Mullane & Rosemary Carroll

  2. West Side Veterans Affairs Medical Center, Chicago, IL, USA

    Thomas Lad, Joel Schor, Michael Mullane & Rosemary Carroll

  3. Chicago Osteopathic Medical Center, Chicago, IL, USA

    David Chernicoff

  4. Illinois Cancer Council, Chicago, IL, USA

    Richard Blough & Linda Weidner

Authors
  1. Thomas Lad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joel Schor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Mullane
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rosemary Carroll
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Chernicoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard Blough
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Linda Weidner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lad, T., Schor, J., Mullane, M. et al. Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. Invest New Drugs 10, 27–28 (1992). https://doi.org/10.1007/BF01275475

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01275475

Key words

Search

Navigation